Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amphastar Pharmaceuticals (AMPH) EPS (Weighted Average and Diluted): 2012-2024

Historic EPS (Weighted Average and Diluted) for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Dec 2024 value amounting to $3.06.

  • Amphastar Pharmaceuticals' EPS (Weighted Average and Diluted) fell 52.56% to $0.37 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.26, marking a year-over-year decrease of 24.92%. This contributed to the annual value of $3.06 for FY2024, which is 17.69% up from last year.
  • Latest data reveals that Amphastar Pharmaceuticals reported EPS (Weighted Average and Diluted) of $3.06 as of FY2024, which was up 17.69% from $2.60 recorded in FY2023.
  • In the past 5 years, Amphastar Pharmaceuticals' EPS (Weighted Average and Diluted) ranged from a high of $3.06 in FY2024 and a low of $0.03 during FY2020.
  • Over the past 3 years, Amphastar Pharmaceuticals' median EPS (Weighted Average and Diluted) value was $2.60 (recorded in 2023), while the average stood at $2.47.
  • In the last 5 years, Amphastar Pharmaceuticals' EPS (Weighted Average and Diluted) slumped by 96.94% in 2020 and then spiked by 4,066.67% in 2021.
  • Yearly analysis of 5 years shows Amphastar Pharmaceuticals' EPS (Weighted Average and Diluted) stood at $0.03 in 2020, then spiked by 4,066.67% to $1.25 in 2021, then surged by 39.20% to $1.74 in 2022, then skyrocketed by 49.43% to $2.60 in 2023, then rose by 17.69% to $3.06 in 2024.